Essex Investment Management Co. LLC grew its position in Vericel Corp (NASDAQ:VCEL) by 2.0% during the fourth quarter, according to its most recent 13F filing with the SEC. The institutional investor owned 157,372 shares of the biotechnology company’s stock after buying an additional 3,048 shares during the period. Essex Investment Management Co. LLC owned 0.36% of Vericel worth $2,738,000 at the end of the most recent quarter.
Several other large investors have also recently added to or reduced their stakes in the company. Legal & General Group Plc raised its position in shares of Vericel by 17.1% in the 3rd quarter. Legal & General Group Plc now owns 6,443 shares of the biotechnology company’s stock valued at $91,000 after purchasing an additional 943 shares during the last quarter. Meeder Asset Management Inc. raised its position in Vericel by 28.7% during the 4th quarter. Meeder Asset Management Inc. now owns 5,765 shares of the biotechnology company’s stock worth $100,000 after buying an additional 1,284 shares during the last quarter. Zurcher Kantonalbank Zurich Cantonalbank purchased a new position in Vericel during the 4th quarter worth approximately $44,000. Financial Architects Inc purchased a new position in Vericel during the 4th quarter worth approximately $69,000. Finally, American International Group Inc. raised its position in Vericel by 18.6% during the 3rd quarter. American International Group Inc. now owns 28,505 shares of the biotechnology company’s stock worth $403,000 after buying an additional 4,474 shares during the last quarter. Institutional investors and hedge funds own 79.31% of the company’s stock.
Top 5 Biotech Stocks To Watch For 2019: Amgen Inc.(AMGN)
Advisors' Opinion:- [By Keith Speights]
Amgen (NASDAQ:AMGN) has been the hands-down winner over Celgene (NASDAQ:CELG) in terms of stock performance over the last year. It's the same story for revenue generated. Celgene beat Amgen in earnings, but only because of a technicality: Amgen incurred a big one-time tax hit in 2017.
- [By Dan Caplinger]
The iShares biotech ETF has a structure that's familiar to anyone who invests regularly in exchange-traded funds. The ETF tracks an index of nearly 200 biotech and pharmaceutical stocks, with roughly 80% of assets dedicated to true biotechs and the rest split evenly between pharma and life sciences equipment and services providers. Top ETF holdings Biogen (NASDAQ:BIIB), Amgen (NASDAQ:AMGN), and Gilead Sciences (NASDAQ:GILD) make up a total of roughly 25% of the fund's assets.
- [By ]
Amgen's (NASDAQ:AMGN) past is filled with excitement. The company rose to become one of the biggest biotechs in the world. It grew a product lineup with multiple blockbuster drugs. Over the last decade, Amgen's share price has more than tripled. But the excitement appears likely to diminish considerably for Amgen -- at least for the next few years.
- [By Todd Campbell, Chris Neiger, and Sean Williams]
Whirlpool Corporation (NYSE:WHR), Amgen Inc. (NASDAQ:AMGN), and Microsoft Corporation (NASDAQ:MSFT) are very different companies, but they all share one thing in common: Our Motley Fool contributors think now's a good time to add them to dividend portfolios. What makes these companies special? Read on to learn why Whirlpool could be a bargain-bin buy because of tariffs, Amgen could benefit from dividend growth thanks to new drugs, and Microsoft's big bet on the cloud makes it a savvy buy.
Top 5 Biotech Stocks To Watch For 2019: Biogen Idec Inc(BIIB)
Advisors' Opinion:- [By Todd Campbell]
Unfortunately for investors, June's discovery wasn't exciting enough for Sangamo partners Biogen (NASDAQ:BIIB) and Shire (NASDAQ:SHPG). In 2015, Biogen announced a delay to its beta-thalassemia and sickle-cell disease treatment program with Sangamo. And then Shire, a Sangamo collaboration partner since 2012, walked away from Sangamo's hemophilia program.
- [By Cory Renauer]
Biotech traders get heaps of attention, but buying promising young drugmakers and holding them for the long term is a far easier way to get rich. Case in point: Spreading $10,000 evenly among shares of Biogen Inc. (NASDAQ:BIIB), Celgene Corporation (NASDAQ:CELG), and Gilead Sciences Inc. (NASDAQ:GILD) around this time in 1998 would have made you a millionaire already.
- [By Keith Speights]
Surprising only begins to describe the latest clinical study results announced by Biogen (NASDAQ:BIIB) and its partner, Japanese drugmaker Eisai (NASDAQOTH:ESALY). On July 5, the two companies reported positive topline results from a phase 2 clinical study of experimental Alzheimer's disease drug BAN2401 at 18 months.
- [By Brian Orelli]
Shares of Ionis Pharmaceuticals (NASDAQ:IONS) ended the day down 10.6% after an earnings report from partner Biogen (NASDAQ:BIIB) started the day on a sour note. Then shares dropped even further midday after data was released for IONIS-HTTRx, a treatment for Huntington's disease. Biogen managed to end the day in the green, up 1.1%.
- [By Chris Lange]
Short interest in Biogen Inc. (NASDAQ: BIIB) increased to 4.33 million shares from the previous 3.86 million. The stock recently traded at $306.68 within a 52-week range of $249.17 to $370.57.
- [By Cory Renauer]
Healthcare is something that people need no matter what's happening in the economy, so the sector is full of great stocks for investors seeking steadily growing income streams. That said, Abiomed, Inc. (NASDAQ:ABMD), Biogen Inc. (NASDAQ:BIIB), and Canopy Growth Corporation (NYSE:CGC) are three popular healthcare stocks that would make horrible additions to a retirement portfolio.
Top 5 Biotech Stocks To Watch For 2019: ArQule Inc.(ARQL)
Advisors' Opinion:- [By Stephan Byrd]
Get a free copy of the Zacks research report on ArQule (ARQL)
For more information about research offerings from Zacks Investment Research, visit Zacks.com
- [By Joseph Griffin]
ValuEngine upgraded shares of ArQule (NASDAQ:ARQL) from a buy rating to a strong-buy rating in a research report released on Tuesday.
Several other equities analysts have also issued reports on ARQL. Zacks Investment Research upgraded ArQule from a hold rating to a buy rating and set a $2.50 price objective for the company in a research report on Tuesday, March 20th. BidaskClub upgraded ArQule from a buy rating to a strong-buy rating in a research report on Saturday, March 24th. B. Riley set a $4.00 price objective on ArQule and gave the company a buy rating in a research report on Monday, March 26th. Leerink Swann upgraded ArQule from a market perform rating to an outperform rating in a research report on Thursday, April 5th. Finally, Roth Capital boosted their price objective on ArQule from $5.00 to $6.00 and gave the company a buy rating in a research report on Tuesday, April 17th. One equities research analyst has rated the stock with a sell rating, five have assigned a buy rating and two have issued a strong buy rating to the stock. The company has a consensus rating of Buy and a consensus target price of $5.35.
- [By Max Byerly]
Get a free copy of the Zacks research report on ArQule (ARQL)
For more information about research offerings from Zacks Investment Research, visit Zacks.com
- [By Maxx Chatsko]
Shares of ArQule (NASDAQ:ARQL) rose over 70% today after the company reported full-year 2018 operating results and provided full-year 2019 guidance. That said, investors are probably used to wild swings in the stock price by now. The development-stage pharma didn't turn in a particularly impressive performance last year. Management expects revenue to drop significantly in the year ahead as collaboration revenue dries up, which will also widen operating losses.
Top 5 Biotech Stocks To Watch For 2019: Alnylam Pharmaceuticals Inc.(ALNY)
Advisors' Opinion:- [By Logan Wallace]
Alnylam Pharmaceuticals (NASDAQ:ALNY) was downgraded by analysts at Zacks Investment Research from a hold rating to a sell rating. According to Zacks, “Although Alnylam has a broad and promising pipeline, we note that most candidates are in mid stages of development. These candidates still have a long way to go before hitting the market. The company relies highly on collaborators for funding. Any development/regulatory setback would be a negative for the company. However, Alnylam reported positive data from the ATLAS study in the first quarter which led to regulatory filings for its late-stage pipeline candidate patisiran and the FDA set an action date of Aug 11, 2018. The company along with its partners Sanofi and The Medicines Company, restarted fitusiran's ATLAS phase III study and advanced inclisiran in the ORION-9, -10, and -11 phase III studies, respectively, with results expected for both programs in 2019. Alnylam expects to achieve the profile of three marketed products by the end of 2020.”
- [By Jim Crumly]
You would think that when a drug company that's been working for 16 years to develop drugs using a novel therapeutic approach wins its first-ever approval from the U.S. Food and Drug Administration (FDA), confetti would fall from the ceiling and its investors would be celebrating a huge stock gain the next day. That didn't happen this week for shareholders of Alnylam Pharmaceuticals (NASDAQ:ALNY), with shares dropping 6.6% the day after the announcement, and there were two main reasons for that.
- [By Jim Crumly]
Commercial success for Tegsedi is not a done deal even if it's approved worldwide; Alnylam Pharmaceuticals' (NASDAQ:ALNY) competing drug patisiran was approved by the FDA on Aug. 10. Alnylam's clinical testing showed cardiac benefits for patients whose cardiovascular systems have been affected by the disease, and Alnylam believes that will give patisiran an advantage over Tegsedi. But in the conference call, Akcea executives brushed off that concern and pointed to the advantage Tegsedi has in being an injection that can be delivered at home, versus patisiran, which is administered intravenously in a clinic. We shall see.
- [By Brian Orelli]
Alnylam Pharmaceuticals (NASDAQ:ALNY) updated investors last month on how the launch of Onpattro, its first drug that was approved to treat transthyretin-mediated amyloidosis (ATTR), was going at the J.P. Morgan Healthcare Conference.
No comments:
Post a Comment